MYDA Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

MYDA Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-115,200	Closed	-$510K	–	167
2024 Q4	$510K	Buy	+115,200	New	+$467K	0.13%	95

Other funds holding IRWD

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

MYDA Advisors's IRWD Position: Q1 2025 in Review

MYDA Advisors sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2025, closing a stake of 115,200 shares — an estimated $510K sold.

MYDA Advisors first reported a position in IRWD in Q4 2024 and held it in 1 quarter. The position peaked at $510K in Q4 2024. 200 funds tracked by Wall St. Rank hold IRWD as of Q1 2025.

MYDA Advisors reported no remaining Ironwood Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
MYDA Advisors sold 115,200 Ironwood Pharmaceuticals shares in Q1 2025, an estimated $510K.
MYDA Advisors first reported a position in Ironwood Pharmaceuticals in Q4 2024 and held it in 1 quarter.
MYDA Advisors's Ironwood Pharmaceuticals position peaked at $510K in Q4 2024.
200 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2025.

Based on MYDA Advisors's 13F filing for Q1 2025, filed 14 May 2025.